|Bid||1.9600 x 900|
|Ask||2.1400 x 3200|
|Day's Range||2.0000 - 2.1300|
|52 Week Range||1.3500 - 4.8100|
|Beta (5Y Monthly)||1.39|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...
A handful of small companies are working on long Covid treatments — sorely needed tools as the number of those afflicted grows.
Axcella (AXLA) re-prioritizes its clinical portfolio to focus on the development of AXA1125 targeting long COVID and NASH. It also suspends the development of AXA1665 to focus resources on AXA1125 studies.